CD28 and neoplasm: This control antibody, in marked contrast to XmAb808s, did not increase the antitumor activity of EpCAM×CD3 (Fig. 5A) or boost T-cell counts (Fig. 5C and D), highlighting the requirement for CD28 engagement to generate tumor-targeted costimulation.